Closed-loop insulin delivery systems in patients with pancreatitis or pancreatectomy-induced diabetes: A case series

IF 4.6 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & metabolism Pub Date : 2024-05-24 DOI:10.1016/j.diabet.2024.101544

Menaouar Touimer , Hana Charfi , Antonio Sa Cunha , Alfred Penfornis , Coralie Amadou

{"title":"Closed-loop insulin delivery systems in patients with pancreatitis or pancreatectomy-induced diabetes: A case series","authors":"Menaouar Touimer , Hana Charfi , Antonio Sa Cunha , Alfred Penfornis , Coralie Amadou","doi":"10.1016/j.diabet.2024.101544","DOIUrl":null,"url":null,"abstract":"<div>Pancreatic diabetes is associated with glycemic variability, poor metabolic control, and reduced quality of life. Though hybrid closed-loop (HCL) insulin delivery systems were not originally developed for these types of diabetes, they could address the therapeutic challenge. We aimed to evaluate long-term metabolic control in ten adult patients (mean ± SD age: 59 ± 12) treated with HCL insulin delivery systems for pancreatitis or pancreatectomy-induced diabetes. After a median of 346 days (range 64 - 631) with HCL insulin delivery, continuous glucose monitoring showed 59±19 % time-in-range [70–180 mg/dl] (versus 49±24 % before HCL insulin delivery, P = 0. 049) and 0.8 ± 1.0 % time-below-range [< 70 mg/dl] (versus 2.2 ± 2.6 %, P = 0.142), with the coefficient of glucose variability at 35.4 ± 7.6 (versus 37.8 ± 7.1, P = 0.047). HbA1c decreased from 8.5 ± 1.7 % to 7.7 ± 1.3 % [69±18 to 60±14 mmol/mol] (P = 0.076). No patient experienced an acute adverse metabolic event.</div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1262363624000363","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Pancreatic diabetes is associated with glycemic variability, poor metabolic control, and reduced quality of life. Though hybrid closed-loop (HCL) insulin delivery systems were not originally developed for these types of diabetes, they could address the therapeutic challenge. We aimed to evaluate long-term metabolic control in ten adult patients (mean ± SD age: 59 ± 12) treated with HCL insulin delivery systems for pancreatitis or pancreatectomy-induced diabetes. After a median of 346 days (range 64 - 631) with HCL insulin delivery, continuous glucose monitoring showed 59±19 % time-in-range [70–180 mg/dl] (versus 49±24 % before HCL insulin delivery, P = 0. 049) and 0.8 ± 1.0 % time-below-range [< 70 mg/dl] (versus 2.2 ± 2.6 %, P = 0.142), with the coefficient of glucose variability at 35.4 ± 7.6 (versus 37.8 ± 7.1, P = 0.047). Hb_A1c decreased from 8.5 ± 1.7 % to 7.7 ± 1.3 % [69±18 to 60±14 mmol/mol] (P = 0.076). No patient experienced an acute adverse metabolic event.

查看原文本刊更多论文

胰腺炎或胰腺切除术诱发糖尿病患者的闭环胰岛素输送系统：病例系列

胰腺糖尿病与血糖变化、代谢控制不佳和生活质量下降有关。虽然混合闭环（HCL）胰岛素给药系统最初并不是针对这类糖尿病开发的，但它们可以解决治疗难题。我们的目的是评估十名成年患者（平均年龄（± SD）：59±12 岁）在接受 HCL 胰岛素输送系统治疗胰腺炎或胰腺切除术诱发的糖尿病后的长期代谢控制情况。在使用 HCL 胰岛素给药的中位数 346 天（64 - 631 天）后，连续血糖监测显示在[70-180 mg/dl]范围内的时间为 59±19 %（与使用 HCL 胰岛素给药前的 49±24 % 相比，P = 0.049）和 0.8 ± 1.0 % 的时间低于范围 [< 70 mg/dl]（与之相比为 2.2 ± 2.6 %，P = 0.142），葡萄糖变异系数为 35.4 ± 7.6（与之相比为 37.8 ± 7.1，P = 0.047）。HbA1c 从 8.5 ± 1.7% 降至 7.7 ± 1.3% [69±18 降至 60±14 mmol/mol]（P = 0.076）。没有患者发生急性代谢不良事件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes & metabolism 医学-内分泌学与代谢

CiteScore

12.00

自引率

4.20%

发文量

审稿时长

13 days

期刊介绍： A high quality scientific journal with an international readership Official publication of the SFD, Diabetes & Metabolism, publishes high-quality papers by leading teams, forming a close link between hospital and research units. Diabetes & Metabolism is published in English language and is indexed in all major databases with its impact factor constantly progressing. Diabetes & Metabolism contains original articles, short reports and comprehensive reviews.